The yellow fever mosquito, *Aedes aegypti*, is the principal vector of many arboviruses, such as dengue, chikungunya, yellow fever, and zika. These pathogens are globally widespread and pose significant epidemiological burdens on infected populations, resulting in hundreds of millions infections and over 50,000 deaths per year ([@r1][@r2][@r3]--[@r4]). Due to the hazards they impose, many methods for controlling *Ae. aegypti* populations have been implemented, with the most common being chemical insecticides. However, chemical control has proven incapable of stopping the spread of *Ae. aegypti*, primarily due to the mosquito\'s ability to rapidly adapt to new climates, tendency to oviposit in minimal water sources, desiccation-tolerant eggs, and quick development of insecticide resistance ([@r5], [@r6]). Therefore, significant efforts are currently underway to discern the underlying molecular and genetic mechanisms important for arboviral vector competence, with the overall aim of developing insecticide-free ways to disrupt viral disease cycles ([@r7]). Importantly, uncovering these mechanisms hinges on the ability to stably insert and disrupt specific genes-of-interest through tailored genome engineering in a target-specific manner. Fortunately, several tools have been successfully employed in mosquitoes for targeted genome engineering that rely on either zinc finger nucleases ([@r8][@r9]--[@r10]), transcription activator-like effector nucleases (TALENs) ([@r11], [@r12]), or even homing endonuclease genes ([@r13]). However, because they rely on context-sensitive modular protein--DNA-binding interactions, each of these designer nucleases are time-consuming and complicated to engineer and validate, making them onerous for routine use in most laboratories.

To overcome the significant limitations posed by previous genome-editing tools, the clustered regularly interspaced short palindromic repeats/CRISPR-associated sequence 9 (CRISPR/Cas9) system, originally discovered in bacteria and archaea ([@r14][@r15][@r16][@r17][@r18][@r19]--[@r20]), has been adapted as a programmable ([@r20], [@r21]) precision genome-editing tool in a diversity of organisms ([@r22][@r23][@r24][@r25][@r26][@r27][@r28]--[@r29]), including mosquitoes ([@r30][@r31][@r32][@r33]--[@r34]). Briefly, the CRISPR/Cas9 system is guided by a chimeric programmable synthetic short-guide RNA (sgRNA) ([@r20]) that binds Cas9, directing it to a user-specified genomic DNA target sequence, via Watson--Crick base pairing between the sgRNA and the target DNA sequence, thereby generating site-specific double-strand (ds) DNA breaks. This system can be easily reprogrammed to modify virtually any desired genomic sequence by recoding the specificity-determining sequence of the sgRNA. Recoding constraints are minimal and simply require that the target sequence is unique, compared with the rest of the genome, and is located just upstream of a protospacer adjacent motif (PAM sequence), typically consisting of the three nucleotide motif NGG ([@r20], [@r21]). Both the minimal constraints and ease of use make CRISPR/Cas9 a powerful tool for genome-engineering applications.

Importantly, CRISPR-mediated genome engineering of organisms has been achieved in a variety of different ways. For example, direct injection of in vitro-purified sgRNAs combined with either purified Cas9 RNA, recombinant Cas9 protein, or even with Cas9 expression plasmids, have all been successful for a variety of organisms ([@r29], [@r32], [@r35][@r36][@r37][@r38][@r39]--[@r40]), including mosquitoes ([@r30][@r31][@r32][@r33]--[@r34]). However, the rate of mutagenesis and lethality have varied widely, both within and among these different studies, and such discrepancies are likely due to either the methods used to introduce the editing components, the variability in sgRNA functionality against target sites, or even unavoidable variability from manual injection of the components ([@r41]). To overcome these significant limitations, previous studies in other organisms have shown that stably expressing a transgenic provision of Cas9 in the germline can decrease toxicity to injected embryos, increase the rates of mutagenesis generated by both nonhomologous end joining (NHEJ) and homology-directed repair (HDR), and can also increase the rates of germline transmission of the disrupted allele to offspring ([@r27], [@r41][@r42][@r43][@r44][@r45]--[@r46]).

Germline expression of Cas9 is also essential for developing innovative technologies that rely on "gene drive," which is a novel strategy proposed for the control of vector-borne diseases by rapidly spreading alleles in a population through super-Mendelian inheritance ([@r47], [@r48]). In mosquitoes, gene drives could potentially be used to rapidly disseminate a genetic payload that reduces pathogen transmission throughout a population, thereby suppressing vector competence and human disease transmission. Other possible applications include the suppression of the population by spreading alleles that impair fertility or viability ([@r49], [@r50]). A CRISPR homing-based gene-drive element consists of only a few components, such as an sgRNA and a germline-expressed Cas9 endonuclease that is positioned opposite its target site in the genome. The drive encodes the editing machinery (i.e., Cas9 and sgRNA), allowing it to cut the opposite allele and copy itself into this disrupted allele via HDR, thereby converting a heterozygote into a homozygote, enabling rapid invasion of the drive into a population. In fact, Cas9 has been used to develop highly promising homing-based gene drives in a number of organisms, including yeast ([@r51]), *Drosophila* ([@r52]), and *Anopheles* mosquitoes ([@r52], [@r53]); however, such a system has yet to be developed in *Ae. aegypti*.

We therefore aimed to develop a CRISPR/Cas9 transgenic system that would enable more robust and widespread *Ae. aegypti* genome-engineering applications, including disrupting genes important for vector competence, while also laying the foundation for the future development of gene drives. To do so, we utilized several previously described transcriptional regulatory elements ([@r54], [@r55]), many of which are active in the germline ([@r56]), to drive expression of *Streptococcus pyogenes* Cas9 in *Ae. aegypti*. In total, we developed six independent Cas9 expressing strains, and herein characterize and demonstrate their effectiveness for gene disruption and gene insertion via HDR. We demonstrate the efficiency of using these strains by disrupting six genes in *Ae. aegypti*, giving rise to severe phenotypes, such as having an extra eye (triple eyes), an extra maxillary palp (triple maxillary palps), a nonfunctional curved proboscis, malformed wings, eye pigmentation deficiencies, and pronounced whole-animal cuticle coloration defects. Furthermore, we also demonstrate the ease of generating double- and triple-mutant strains simultaneously from a single injection, a technique that will facilitate the ease of gene-function study in this nonmodel organism. Overall, gene-disruption efficiencies, survival rates, germline-transmission frequencies, and HDR rates were all significantly improved using the Cas9 strains we develop here. These strains should be highly valuable for facilitating the development of innovative control methods in this organism in the future.

Results {#s1}
=======

Construction of a Simple Transgenic CRISPR/Cas9 System for *Ae. aegypti* Mutagenesis. {#s2}
-------------------------------------------------------------------------------------

To express Cas9 in the germline of *Ae. aegypti*, we established transgenic mosquitoes harboring genomic sources of Cas9. To promote robust expression of Cas9, we utilized promoters from six genes including AAEL010097 (*Exuperentia*), AAEL007097 (4-nitrophenylphosphatase), AAEL007584 (*trunk*), AAEL005635 (*Nup50*), AAEL003877 (*polyubiquitin*), and AAEL006511 (*ubiquitin L40*), due to their constitutive high levels of expression during many developmental life stages (AAEL003877, AAEL006511, AAEL005635), or high levels of expression in the ovary triggered by uptake of a blood meal (AAEL010097, AAEL007097, AAEL007584), as evidenced from previous promoter characterization experiments or developmental transcriptional profiling ([@r54][@r55]--[@r56]) ([Fig. 1 *A* and *B*](#fig01){ref-type="fig"}). We inserted these various promoter fragments into a *piggybac* transposon upstream of the coding sequence for spCas9. Downstream to the promoter-driven Cas9 we included a self-cleaving T2A peptide and eGFP coding sequence, together serving as a visual indicator of promoter activity. We also included a baculovirus-derived Opie2 promoter ([@r57]) driving dsRed expression serving as a transgenesis marker ([Fig. 1*C*](#fig01){ref-type="fig"}). The *piggybac* transgenes were injected into the germline of wild-type embryos (*Ae. aegypti* genome sequence strain Liverpool) ([@r58]), and transgenic mosquitoes harboring these transgenes were readily identified by bright dsRed fluorescent expression in the abdomen ([*SI Appendix*, Fig. S1](#d35e543){ref-type="supplementary-material"}). We established stable transgenic strains and dissected the germline tissues from each strain to assess promoter activity, and found moderate levels of eGFP present in the 0- to 24-h postblood meal ovary of the AAEL006511-Cas9 and AAEL010097-Cas9 line, and very-weak yet detectable levels of eGFP present in lines AAEL007097-Cas9, AAEL007584-Cas9, and AAEL005635-Cas9. The AAEL010097-Cas9 and AAEL006511-Cas9 lines also exhibited very-weak expression in the 4-d-old testes. Finally, the AAEL003877-Cas9 line exhibited no detectable eGFP signal, consistent with previous work indicating this promoter does not express in the germline ([@r55]) ([Fig. 1*D*](#fig01){ref-type="fig"}). Importantly, we were able to establish homozygous stocks for each line, demonstrating that no significant toxicity is associated with high transgenic expression of Cas9.

![Rationally chosen, native promoters drive strong expression of Cas9. Log~2~ RPKM expression values for AAEL010097, AAEL007097, AAEL007584, AAEL005635, AAEL003877, and AAEL006511 were plotted across development. Samples include, from left to right: testis; male carcasses (lacking testes); carcasses of females before blood feeding (NBF), and at 12-, 24-, 36-, 48-, and 72-h postblood meal (PBM); ovaries from NBF females and at 12-, 24-, 36-, 48-, and 72-h PBM; embryos from 0--2 h through 72--76 h; whole larvae from first, second, third, and fourth instar; male pupae; female pupae (*A*). Genome browser snapshots of AAEL010097, AAEL007097, AAEL007584, AAEL005635, AAEL003877, and AAEL006511, including expression tracks for both 72-h PBM ovaries and testes. The light gray box indicates coding sequence; blue box represents promoter element with length indicated in bp; *y* axis shows the expression level based on raw read counts (*B*). Schematic representation of the piggybac-mediated Cas9 construct including the *S. pyogenes Cas9*-T2A-eGFP gene driven by selected promoters (blue), dsRed expressed under the control of the Opie2 promoter, which serves as a transgenesis marker. NLS represent nuclear localization signal (*C*). Confocal images using white light or GFP-filtering of transgenic Cas9 line ovaries (*D*). (Magnification, 200×.)](pnas.1711538114fig01){#fig01}

Germline Expression of Cas9 in *Ae. aegypti* Increases Targeting Efficiency. {#s3}
----------------------------------------------------------------------------

To test the efficacy of our transgenic *Ae. aegypti* Cas9 strains, we first attempted to mutate the *kynurenine hydroxylase* (*kh*) gene (AAEL008879), which was previously characterized as having an easily detectable dominant mutant eye phenotype, as the loss of *kh* gene function leads to severe eye pigmentation defects ([@r31]). To do so, we designed a sgRNA (Kh-sgRNA) targeting exon 4 of the *kh* gene, and to test its functionality we coinjected this in vitro-transcribed Kh-sgRNA into 450 wild-type embryos \[referred to as generation 0 (G~0~)\] along with purified recombinant Cas9 protein. Following injection, complete white-eye and partial mosaic white-eye mutants were readily observed in adults ([*SI Appendix*, Fig. S2](#d35e543){ref-type="supplementary-material"}). The G~0~s had a survival rate of 35 ± 7% and a mutagenesis efficiency of 17 ± 3%, and a mutant heritability rate of 33 ± 7% in the G~1~ generation ([Table 1](#t01){ref-type="table"}). Once we confirmed functionality of the Kh-sgRNA using purified recombinant Cas9 protein, we then injected this Kh-sgRNA separately into 450 embryos (three injections of 150 embryos in biological triplicate) collected from each of our transgenic *Ae. aegypti* Cas9 strains without including recombinant Cas9 protein ;in the injection mix. Complete white-eye and mosaic white-eye mutants were readily observed in injected G~0~ mosquitoes from five of six lines, including AAEL010097-Cas9, AAEL007097-Cas9, AAEL007584-Cas9, AAEL005635-Cas9, and AAEL006511-Cas9. Notably, directly injecting Kh-sgRNAs into these transgenic Cas9 expression lines resulted in significantly higher G~0~ survival rates (61 ± 7%, 53 ± 4%, 63 ± 4%, 64 ± 6%, and 63 ± 4%, respectively), increased G~0~ mutagenesis efficiencies (85 ± 5%, 27 ± 6%, 52 ± 7%, 47 ± 3%, and 66 ± 4%, respectively), and increased overall heritable G~1~ mutation rates (60 ± 9%, 59 ± 6%, 59 ± 5%, 60 ± 6%, and 66 ± 3%, respectively) compared with when Kh-sgRNA was coinjected with recombinant Cas9 protein into wild-type embryos ([Table 1](#t01){ref-type="table"}). As reported previously, homozygous viable *kh* mutants have a dramatic eye pigmentation defect that can be visualized in larvae, pupae, and adults ([@r31]) ([Fig. 2*A*](#fig02){ref-type="fig"}). To confirm the phenotypic defects described above were due to mutagenesis of the *kh* gene, genomic DNA spanning the target site was amplified from homozygous mutant G~1~s ([Fig. 2*A*](#fig02){ref-type="fig"}) and sequenced, confirming the presence of insertion/deletions (indels) in the Kh-sgRNA genomic DNA target site ([*SI Appendix*, Fig. S3](#d35e543){ref-type="supplementary-material"}). In contrast, Kh-sgRNA injected directly into the AAEL003877-Cas9 strain failed to show any visible mutant phenotypes in the G~0~ generation, presumably due to lack of germline expression by this promoter ([@r55]).

###### 

Summary of the injection, survival, and mutagenesis rates mediated by Kh-sgRNA, W1-sgRNA, and Y-sgRNA in wild-type and Cas9-expressing lines

  *Ae. aegypti* line      Injected component[\*](#tfn1){ref-type="table-fn"}   No. injected G~0~s   G~0~ adult survivors, %   G~0~ mosaic, %         G~1~ mutant adult[^†^](#tfn2){ref-type="table-fn"}, %
  ----------------------- ---------------------------------------------------- -------------------- ------------------------- ---------------------- -------------------------------------------------------
  Liverpool (wild-type)   Kh-sgRNA,W1-sgRNA,Y-sgRNA                            450, 450, 450        67 ± 4,63 ± 5,61 ± 4      0, 0, 0                0, 0, 0
  Liverpool (wild-type)   Cas9 protein                                         450, 450, 450        39 ± 4,41 ± 4,44 ± 7      0, 0, 0                0, 0, 0
  Liverpool (wild-type)   Kh-sgRNA,W1-sgRNA,Y-sgRNA /Cas9 protein              450, 450, 450        35 ± 7,40 ± 6,30 ± 8      17 ± 3,21 ± 3,18 ± 6   33 ± 7,32 ± 5,30 ± 6
  AAEL010097-Cas9         Kh-sgRNA,W1-sgRNA,Y-sgRNA                            450, 450, 450        61 ± 7,71 ± 6,65 ± 7      85 ± 5,87 ± 6,90 ± 5   60 ± 9,69 ± 4,62 ± 4
  AAEL007097-Cas9         Kh-sgRNA,W1-sgRNA,Y-sgRNA                            450, 450, 450        53 ± 4,58 ± 4,62 ± 9      27 ± 6,33 ± 4,31 ± 5   59 ± 6,56 ± 6,62 ± 5
  AAEL007584-Cas9         Kh-sgRNA,W1-sgRNA,Y-sgRNA                            450, 450, 450        63 ± 4,55 ± 7,61 ± 5      52 ± 7,63 ± 8,57 ± 5   59 ± 5,51 ± 7,57 ± 9
  AAEL005635-Cas9         Kh-sgRNA,W1-sgRNA,Y-sgRNA                            450, 450, 450        64 ± 6,67 ± 3,55 ± 4      47 ± 3,62 ± 7,49 ± 4   60 ± 6,50 ± 6,54 ± 4
  AAEL003877-Cas9         Kh-sgRNA,W1-sgRNA,Y-sgRNA                            450, 450, 450        51 ± 9,61 ± 8,61 ± 7      0, 0, 0                0, 0, 0
  AAEL006511-Cas9         Kh-sgRNA,W1-sgRNA,Y-sgRNA                            450, 450, 450        63 ± 4,57 ± 5,59 ± 6      66 ± 4,73 ± 6,70 ± 7   66 ± 3,65 ± 3,67 ± 4

Biological triplicate consisting of three independent injections (each injection replicate with 150 embryos total 450 embryos) were performed and the results are shown as the mean ± SE throughout table.

sgRNA 100 ng/μL; Cas9 protein 300 ng/μL.

The overall heritable mutation rate was calculated as the number of mutant G~1~s divided by the number of all G~1~s observed.

![Severe mutant phenotypes caused by CRISPR/Cas9 mediated disruption. Larva, pupae, and adult phenotypes of wild-type, *kh*, *white*, *yellow*, and *ebony* mutant G~1~s, respectively, with clearly distinguishable eye (*kh* and *white*) and cuticle pigment (*yellow* and *ebony*) defects (*A*). Embryo phenotypes of wild-type (*Left*) and *yellow* mutants (*Right*) (*B*). Pupae and adult scanning electron microscopy images of the head of the *deformed* G~0~ mutants with three compound eyes (Ce), three maxillary palps (Mp), furrowed eyes, and deformed mouthparts (arrows) (*C*). Pupae and adult scanning electron microscopy images of the head of the *sine oculis* G~0~ mutants. Arrows point to the ectopic eyes (*D*). Images of pupae and adult wings of *vestigial* G~0~ mutants. Arrows point to pronounced wing, halteres, and forked wing defects (*E*). (Magnifications: whole-body images, 20×; *Insets*, 100×; SEM images, 150×.)](pnas.1711538114fig02){#fig02}

Given that CRISPR/Cas9 targeting efficiency varies significantly between loci and even between target sites within the same locus ([@r26], [@r27], [@r30], [@r36]), we wanted to further investigate the efficacy of these transgenic Cas9 expressing strains. We therefore designed two additional sgRNAs targeting uncharacterized conserved genes that may be useful for developing future control methodologies *Ae. aegypti*. One sgRNA (W1-sgRNA) was designed to target exon 3 of the *white* gene (AAEL016999) ([*SI Appendix*, Fig. S4*A*](#d35e543){ref-type="supplementary-material"}), which is the *Aedes* 1:1 ortholog to *Drosophilia melanogaster white* and functions as an ATP-binding cassette transporter important for red and brown eye-color pigmentation ([@r59], [@r60]). Another sgRNA was designed to target exon 2 of the *yellow* gene (AAEL006830) ([*SI Appendix*, Fig. S5*A*](#d35e543){ref-type="supplementary-material"}), which is the *Aedes* 1:1 ortholog to *D. melanogaster yellow*, a gene important for melanization of the cuticle ([@r61], [@r62]). To initially test their functionality, we coinjected either in vitro-transcribed W-sgRNA or Y-sgRNA, separately, into 450 wild-type embryos (three injections of 150 embryos in biological triplicate), each along with purified recombinant Cas9 protein. Following injection, complete white-eye and partial mosaic white-eye, or complete yellow-body and partial mosaic yellow-body mutants were readily observed in G~0~s, indicating that the sgRNAs are functional ([Table 1](#t01){ref-type="table"} and [*SI Appendix*, Fig. S2*A*](#d35e543){ref-type="supplementary-material"}). Once sgRNA functionality was confirmed using recombinant Cas9 protein, we then injected these sgRNAs separately into 450 embryos (three injections of 150 embryos in biological triplicate) collected from each of our transgenic *Ae. aegypti* Cas9-expressing strains without including recombinant Cas9 protein in the injection mix. Similar to the Kh-sgRNA results described above, remarkably higher survival rates, mutagenesis efficiencies, and heritable mutation rates were also achieved for both W-sgRNA and Y-sgRNA when injected into all transgenic Cas9 lines, except AAEL003877-Cas9 ([Table 1](#t01){ref-type="table"}). As in other Dipterans, homozygous G~1~ mutants for *white* have dramatic eye pigmentation defects, similar to the *kh* mutants, which can be visualized in larvae, pupa, and adults ([Fig. 2*A*](#fig02){ref-type="fig"}). Additionally, homozygous G~1~ mutants for *yellow* have a striking yellow cuticle pigmentation defect that can be visualized in, larvae, pupae, adults, and even eggs ([Fig. 2 *A* and *B*](#fig02){ref-type="fig"}). To confirm the phenotypic defects from these sgRNAs were due to mutagenesis of the *white* and *yellow* genes, genomic DNA from homozygous mutant G~1~s ([Fig. 2*A*](#fig02){ref-type="fig"}) was amplified spanning the target sites and sequenced confirming the presence of indels in both the W-sgRNA and Y-sgRNA genomic DNA target sites ([*SI Appendix*, Figs. S4 and S5](#d35e543){ref-type="supplementary-material"}). Altogether, these results indicate that the *Ae. aegypti* transgenic Cas9 expression system that we generated can effectively express Cas9 protein, and direct injection of in vitro-transcribed sgRNAs is sufficient to rapidly disrupt function of target genes of interest and generate highly heritable mutations. Of all of the transgenic lines, the AAEL010097-Cas9 line consistently showed the highest survival rate and efficiency of mutagenesis. Therefore, we performed all subsequent experiments using this strain.

Precise Gene Disruption in *Ae. aegypti*. {#s4}
-----------------------------------------

To further measure the efficacy of the AAEL010097-Cas9 line, we decided to target additional genes causing readily visible phenotypes in related organisms that have yet to be studied in *Ae. aegypti*. Specifically, we chose genes AAEL005793, AAEL009950, AAEL009170, and AAEL003240, which are conserved 1:1 orthologs with the *D. melanogaster* genes *ebony*, *deformed*, *vestigial*, and *sine oculis*, respectively. *Ebony* encodes the enzyme *N*-β-alanyl dopamine (NBAD) synthetase that converts dopamine to NBAD. Loss of ebony function increases black cuticle pigment in *D. melanogaster* ([@r63]). *Deformed* is a homeobox-containing (Hox) transcription factor, loss-of-function of this gene results in dramatic defects in derivatives of the maxillary segments, mandibular segments, and anterior segments in *D. melanogaster* ([@r64]). *Vestigial* encodes a nuclear protein that plays a central role in the development of the wings and loss of *vestigial* results in the failure of proper wing development in *D. melanogaster* ([@r65], [@r66]). The *sine oculis* locus encodes a homeodomain-containing protein, which plays an essential role in eye development and loss of *sine oculis* function leads disruption of the eye disk formation in *D. melanogaster* ([@r67], [@r68]).

To disrupt these genes, a single sgRNA was designed (E-sgRNA, D-sgRNA, So-sgRNA, V-sgRNA) to target an exon in each of these genes ([*SI Appendix*, Figs. S6--S9](#d35e543){ref-type="supplementary-material"}), and then individually injected into 200 AEL010097-Cas9 embryos. Injection of E-sgRNA resulted in 82% of G~0~s showing pronounced dark coloration of the adult cuticle ([*SI Appendix*, Fig. S2](#d35e543){ref-type="supplementary-material"}). These mutations were heritable and we established homozygous viable stocks by pairwise mating G~1~s ([Fig. 2*A*](#fig02){ref-type="fig"} and [Table 2](#t02){ref-type="table"}). D-sgRNA injection resulted in the death of more than 72% of G~0~ mosquitoes before the pupal stage, indicating that this gene is critical for proper development. However, 87% of the mosquitoes that reached adulthood exhibited severe mutant phenotypes including an extra eye (triple eyes), mal-shaped proboscis, and even an extra maxillary palp (triple maxillary palps) ([Fig. 2*C*](#fig02){ref-type="fig"} and [Table 2](#t02){ref-type="table"}). Unsurprisingly, all surviving G~0~ mutant females failed to blood feed, preventing us from establishing homozygous mutant lines. In So-sgRNA injected mosquitoes, 61% of the surviving G~0~s had clearly visible eye defects do to cell death in the primordium region ([Fig. 2*D*](#fig02){ref-type="fig"} and [Table 2](#t02){ref-type="table"}). As with the *deformed* mutants, we were unable to establish homozygous *sine oculis* mutant lines because these mutations were homozygous-lethal. Finally, 70% of V-sgRNA-injected G~0~s died at the pupal stage, with many of the dead pupae showing deformed rudimentary wing appendages ([Fig. 2*E*](#fig02){ref-type="fig"}). Of the few individuals that survived to adulthood, 75% had undeveloped wings or halteres ([Fig. 2*E*](#fig02){ref-type="fig"} and [Table 2](#t02){ref-type="table"}), inhibiting their ability to fly or mate, making it impossible to establish homozygous mutant lines for this gene. To confirm that the phenotypes described above were caused by disruption of the specific genes targeted by the sgRNAs (E-sgRNA, D-sgRNA, So-sgRNA, V-sgRNA), genomic DNA from the mutants ([Fig. 2 *C*--*E*](#fig02){ref-type="fig"}) was amplified spanning the target sites and sequenced confirming a selection of indels in both the genomic DNA target sites ([*SI Appendix*, Figs. S6--S9](#d35e543){ref-type="supplementary-material"}).

###### 

Summary of the injection, survival, and mutagenesis rates mediated by E-sgRNA, D-sgRNA, So-sgRNA, and V-sgRNA in AAEL010097-Cas9 line

  *Ae. aegypti* line   Injected component[\*](#tfn3){ref-type="table-fn"}   No. injected G~0~s   G~0~ larva survivors (%)   G~0~ adult survivors (%)   G~0~ mutant adult (%)   G~1~s mutant adult[^†^](#tfn4){ref-type="table-fn"} (%)
  -------------------- ---------------------------------------------------- -------------------- -------------------------- -------------------------- ----------------------- ---------------------------------------------------------
  AAEL010097-Cas9      E-sgRNA                                              200                  115 (58)                   112 (56)                   92 (82)                 751 (67)
  AAEL010097-Cas9      D-sgRNA                                              200                  122 (61)                   33 (28)                    29 (87)                 Lethal
  AAEL010097-Cas9      So-sgRNA                                             200                  104 (52)                   98 (52)                    59 (61)                 Lethal
  AAEL010097-Cas9      V-sgRNA                                              200                  134 (67)                   40 (30)                    22 (75)                 Lethal

sgRNA 100 ng/μL.

The overall heritable mutation rate was calculated as the number of mutant G~1~s divided by the number of all G~1~s observed.

Multiple sgRNAs Dramatically Improve Mutagenesis Rates. {#s5}
-------------------------------------------------------

To determine if simultaneous injection of two sgRNAs into the embryos of the AAEL010097-Cas9 line could induce higher mutagenesis efficiencies and germline transmission rates, we designed another sgRNA (W2-sgRNA) also targeting exon 3 of the *white* gene ([*SI Appendix*, Fig. S10](#d35e543){ref-type="supplementary-material"}). Initially we tested functionality of the W2-sgRNA by coinjecting this guide with recombinant Cas9 protein into wild-type embryos. We found that this W2-sgRNA is efficient at generating mutations as 41 ± 7% of injected embryos survived to adult, 19 ± 6% of adult survivors showed the mosaic and white-eye mutant phenotypes, and 27 ± 5% G~1~s showed the mutant white-eye phenotype ([Table 3](#t03){ref-type="table"}). Similar to results described above, directly injecting the W2-sgRNA into the embryos of the AAEL010097-Cas9 line, resulted in higher survival rates (62 ± 6%), greater mutagenesis efficiencies (67 ± 9%), and higher germline transmission rates (56 ± 9%) ([Table 3](#t03){ref-type="table"}). Importantly, when we coinjected W1-sgRNA (described above) and W2-sgRNA together into embryos of the AAEL010097-Cas9 line, *white* mutants were obtained in the G~0~s at an extremely higher frequency of 94 ± 3%, with a remarkable G~1~ transmission frequency of 96 ± 3% ([Table 3](#t03){ref-type="table"}). Furthermore, genomic sequencing confirmed that some of the injections generated large deletions spanning the genomic distance (∼350 bp) between the W1-sgRNA and W2-sgRNA target sites ([*SI Appendix*, Fig. S10](#d35e543){ref-type="supplementary-material"}). Together, these results indicate that by simultaneous injection of multiple sgRNAs targeting the same gene, higher mutagenesis rates and large deletions can be readily achieved.

###### 

Summary of the injection, survival, and mutagenesis rates mediated by W1-sgRNA and W2-sgRNA in wild-type and AAEL010097-Cas9 line

  *Ae. aegypti* line      Injected component[\*](#tfn5){ref-type="table-fn"}   No. injected G~0~s   G~0~ adult survivors, %   G~0~ mosaic, %   G~1~s mutant adult[^†^](#tfn6){ref-type="table-fn"} %
  ----------------------- ---------------------------------------------------- -------------------- ------------------------- ---------------- -------------------------------------------------------
  Liverpool (wild-type)   W2-sgRNA /Cas9 protein                               450                  41 ± 7                    19 ± 6           27 ± 5
  Liverpool (wild-type)   W1-sgRNA/W2-sgRNA /Cas9 protein                      450                  37 ± 5                    34 ± 5           37 ± 9
  AAEL010097-Cas9         W2-sgRNA                                             450                  62 ± 6                    67 ± 9           56 ± 9
  AAEL010097-Cas9         W1-sgRNA/W2-sgRNA                                    450                  61 ± 8                    94 ± 3           96 ± 3

Biological triplicate consisting of three independent injections (each injection replicate with 150 embryos total 450 embryos) were performed and the results are shown as the mean ± SE throughout table.

sgRNA 100 ng/μL; Cas9 protein 300 ng/μL.

The overall heritable mutation rate was calculated as the number of mutant G~1~s divided by the number of all G~1~s observed.

Highly Efficient Multiplex Gene Disruption from a Single Injection. {#s6}
-------------------------------------------------------------------

Given the laborious and time-consuming crossing required to generate *Ae. aegypti* lines with mutations at multiple genes, we explored whether double- or triple-gene knockout strains could quickly be generated in one step by coinjecting a multiplexed combination of sgRNAs targeting different genes. To do so, we made four mixes, including three combinations of two sgRNAs, including: W1-sgRNA and Y-sgRNA (mix 1); W1-sgRNA and E-sgRNA (mix 2); Y-sgRNA and E-sgRNA (mix 3); and one combination of three sgRNAs, W1-sgRNA, Y-sgRNA and E-sgRNA (mix 4). We injected these four mixes separately into 200 embryos from the AAEL010097-Cas9 line. We found that 90%, 87%, 93%, and 94% of the G~0~-injected survivors contained at least one mutant phenotype for the injection sets one to four, respectively ([Table 4](#t04){ref-type="table"}). Furthermore, 90%, 88%, and 92% of the G~0~ injected survivors had double-mutants when injected with sets one to three, respectively ([Table 4](#t04){ref-type="table"} and [*SI Appendix*, Fig. S11](#d35e543){ref-type="supplementary-material"}). When we coinjected a combination of three sgRNA (mix 4), we found that 67% of the surviving G~0~ adults contained mutations in all three genes targeted ([Table 4](#t04){ref-type="table"} and [*SI Appendix*, Fig. S11](#d35e543){ref-type="supplementary-material"}). Furthermore, these mutations were heritable as homozygous viable mutant stocks following pairwise mating of G~1~ multimutants ([Fig. 3](#fig03){ref-type="fig"}). Together, these results demonstrate that simultaneous and heritable multiple gene disruptions can be efficiently achieved by using transgenic expression of Cas9 and this simple technique should facilitate the rapid understanding of gene function and help tease apart gene networks in this nonmodel organism.

###### 

Single injection of multiple sgRNAs into the embryos of AAEL010097-Cas9 line results in highly efficient rates of multigene disruption

  Injected sgRNAs            Injected embryos   G~0~ adult survivors (%)   G~0~ mosaic (%)   Single mutant G~0~s (%); G~1~s[\*](#tfn7){ref-type="table-fn"} (%)   Double-mutant G~0~s (%); G~1~s[^†^](#tfn8){ref-type="table-fn"} (%)   Triple-mutant G~0~s (%); G~1~s[^‡^](#tfn9){ref-type="table-fn"} (%)                                                               
  -------------------------- ------------------ -------------------------- ----------------- -------------------------------------------------------------------- --------------------------------------------------------------------- --------------------------------------------------------------------- ------------------- ------------------- ------------------- ------------------
  W1-sgRNA/Y-sgRNA           200                122 (61)                   110 (90)          4 (4); 170 (15)                                                      7 (6); 238 (21)                                                       N/A, N/A                                                              99 (90); 488 (43)   N/A; N/A            N/A; N/A            N/A; N/A
  W1-sgRNA/E-sgRNA           200                113 (56)                   98 (87)           7 (7); 141 (17)                                                      N/A; N/A                                                              5 (5); 224 (27)                                                       N/A; N/A            86 (88); 390 (47)   N/A; N/A            N/A; N/A
  Y-sgRNA/E-sgRNA            200                102 (51)                   95 (93)           N/A; N/A                                                             3 (3); 343(25)                                                        5 (5); 261 (15)                                                       N/A; N/A            N/A; N/A            87 (92); 536 (39)   N/A; N/A
  W1-sgRNA/Y-sgRNA/E-sgRNA   200                86 (43)                    81 (94)           3 (4); 85 (11)                                                       3 (4); 54(7)                                                          1 (1); 23 (3)                                                         5 (6); 131 (17)     9 (11); 101 (13)    6 (7); 162 (21)     54 (67); 85 (11)

N/A, not applicable.

Single-mutant phenotype, *W*: white eye; *Y*: yellow body; *E*: dark body.

Double-mutant phenotypes, *W/Y*: white eye and yellow body, *W/E*: white eye and dark body; *Y/E* yellow body and dark body.

Triple-mutant phenotypes, *W/Y/E*: white eye, yellow body, and dark body.

![Single injections of multiplexed sgRNAa robustly generate double- and triple-mutant mosquitoes. Larva, pupae, and adult G~1~ phenotypes for double-mutants, including: yellow body and white eyes (*yellow/white*), a mixture of yellow and dark body (*yellow/ebony*), dark body and white eyes (*ebony/white*), and one triple-mutant, which is a phenotypic mixture of yellow and dark body and white eyes (*yellow/ebony/white*). The striking differences between wild-type and mutant larva, pupae and adult are highlighted. (Magnifications: whole-body images, 20×; *Insets*, 100×.)](pnas.1711538114fig03){#fig03}

Increased Rates of HDR with dsDNA Donors. {#s7}
-----------------------------------------

Given the exceedingly high rate of NHEJ-induced mutation when using theAAEL010097-Cas9 line, we wanted to assess knock-in rates mediated by HDR via dsDNA donors in this line. Our strategy was to employ two donor plasmids, a *white*-donor plasmid based on the W1-sgRNA and a *kh*-donor plasmid based on the Kh-sgRNA. Each of these two donor plasmids was designed to contain a dominant fluorescent marker consisting of 3xP3-dsRed, expressing in the larvae and adult photoreceptors, flanked by ∼1-kb homology arms that were derived from the genomic sequence immediately flanking the target cleavage sites ([Fig. 4 *A* and *B*](#fig04){ref-type="fig"}). We directly compared two approaches: (*i*) coinjection of dsDNA donor combined with in vitro transcribed sgRNA and purified recombinant Cas9 protein into wild-type embryos; and (*ii*) coinjection of circular dsDNA donor combined with in vitro transcribed sgRNA injected into AAEL010097-Cas9 line embryos. For the first approach, a total of 600 embryos were separately injected for both the *white-*donor and *kh*-donor, with a HDR rate of 0.15% and 0.14% ([Table 5](#t05){ref-type="table"}), respectively. For the second approach, a total of 600 embryos from the *Ae. aegypti* AAEL010097-Cas9 line were separately injected for both the *white-*donor and *kh*-donor, with a HDR rate of 2.36% and 2.48% ([Table 5](#t05){ref-type="table"}), respectively. Overall, we see a dramatic, yet consistent, 15- to 17-fold increase in rates of HDR when using the AAEL010097-Cas9 line compared with the nontransgenic method of supplying Cas9. Gene-specific insertion of our donor cassettes into the intended target sites was confirmed by subsequent genomic PCR and sequencing ([Fig. 4 *A*--*C*](#fig04){ref-type="fig"} and [*SI Appendix*, Fig. S12](#d35e543){ref-type="supplementary-material"}).

![Highly efficient site-specific integration via CRISPR-mediated HDR. Schematic representations of the *white* locus and *white*-donor construct (*A*), and the *kh* locus and *kh*-donor construct (*B*). Exons are shown as boxes, coding regions are depicted in black and the 5′ and 3′ UTRs in gray. Locations and sequences of the sgRNA targets are indicated with the PAM shown in yellow. Black arrows indicate approximate positions and directions of the oligonucleotide primers used in the study. The donor plasmids (blue) express fluorescent eye marker (3xp3-DsRed) inserted between regions of homology from the *white* and *kh* locus, respectively (*A* and *B*). Gene amplification analysis confirms site-specific integration of the *white*-donor construct into the *white* locus using combinations of genomic and plasmid donor-specific primers (933Cms3/933Cms4 expected 349 bp, and 933Cms5/933Cms6 expected 533 bp) (*C*), and also confirms the integration of the *kh*-donor construct into the *kh* locus using combinations of genomic and plasmid donor specific primers (924ms3/924ms4 expected 525 bp, and 924ms5/924ms6 expected 745 bp) with no amplification in wild-type (*D*). WT represents wild-type, WD represents knockin with white-donor, KHD represents knockin with *kh-*donor. (Magnification: 20×.)](pnas.1711538114fig04){#fig04}

###### 

Transgenic source of Cas9 results in increased rates of HDR with dsDNA donors

  *Ae. aegypti* strain    Injected component[\*](#tfn10){ref-type="table-fn"}   Injected embryos   Adult G~0~ survivors (%)   HDR event   
  ----------------------- ----------------------------------------------------- ------------------ -------------------------- ----------- ------------------
  Liverpool (wild-type)   W1-sgRNA/Cas9/*white*-donor                           600                251(41.83)                 1/20 (5)    9/5,371 (0.15)
  Liverpool (wild-type)   Kh-sgRNA/Cas9/*kh*-donor                              600                273 (45.50)                1/20 (5)    7/4,773 (0.14)
  AAEL010097-Cas9         W1-sgRNA/*white*-donor                                600                308 (51.33)                4/20 (20)   118/4,993 (2.36)
  AAEL010097-Cas9         Kh-sgRNA/*kh*-donor                                   600                298 (49.67)                5/20 (25)   149/6,017 (2.48)

The concentration of sgRNA is 100 ng/μL; Cas9 protein 300 ng/μL. *white*-donor and *kh*-donor plasmids 100 ng/μL.

Discussion {#s8}
==========

Previous studies have demonstrated effective CRISPR/Cas9 genome editing in the mosquito *Ae. aegypti* ([@r30][@r31][@r32][@r33]--[@r34]); however, these studies utilized a nontransgenic source of Cas9, limiting both survivorship and editing efficiencies. To overcome these previous limitations, and to reduce the complexity of injecting multiple components (i.e., Cas9 and sgRNA), herein we developed a simplified transgenic Cas9 expression system in *Ae. aegypti*, similarly to what is routinely used in other organisms such as *D. melanogaster* ([@r27], [@r41], [@r42]). Importantly, to achieve highly specific and consistent genome modifications, we demonstrate that embryos from these Cas9 strains need only be injected with easy-to-make sgRNAs. By using these Cas9 strains, we disrupted multiple genes that were either homozygous viable (*kh*, *white*, *yellow*, and *ebony*), or homozygous lethal (*deformed*, *sine oculis*, *vestigial*), resulting in dramatic phenotypes affecting viability, vision, flight, and blood feeding, and therefore may be useful for developing control strategies and genetic sexing techniques in the future. For example, in a *yellow* mutant background, the endogenous gene encoding *yellow* could be linked to the male-determining locus ([@r32]), using CRISPR-mediated HDR, to generate a robust genetic sexing system by which male embryos/larvae/adults would be dark and female embryos/larvae/adults would be yellow.

An appealing advantage of our Cas9 transgenic system is the ability to efficiently disrupt multiple genes simultaneously. We have demonstrated that we can efficiently generate large deletions, or even double- (*yellow-white*; *ebony-white*; *yellow-ebony*), or triple- (*yellow-ebony-white*) mutants. Importantly, these multimutants can rapidly be generated in a single-step approach by injecting multiple sgRNAs into the embryos of the transgenic Cas9 strains, significantly reducing downstream efforts. This rapid multiplex gene knockout approach will be instrumental for dissecting gene networks in this nonmodel organism. While the Cas9 strains were generated in the Liverpool genetic background, these strains can be introgressed into other genetic backgrounds if desired.

The germline Cas9 strains developed here may also bring us one step closer to engineering an effective CRISPR/Cas9-homing--based gene drive system ([@r47], [@r48]) in this organism. Homing-based drive systems rely on HDR to convert heterozygous alleles into homozygous alleles in the germline, and have recently been successfully engineered in two *Anopheline* mosquito species ([@r51], [@r69]). While these studies were fruitful at significantly biasing rates of Mendelian inheritance rates of the drive containing alleles, they were severely limited by the rapid evolution of resistance alleles generated by NHEJ, and are therefore not predicted to spread into diverse wild populations ([@r70]). It was hypothesized that these resistance alleles formed due to high levels of maternal deposition of Cas9 in the embryo, and by restricting Cas9 expression to the germline may subsequently increase rates of HDR and reduce rates of NHEJ. In addition to restricting expression to the germline, multiplexing of sgRNAs in the drive, and designing the drive to target a critical gene have also been proposed as innovative strategies to increase rates of HDR and reduce resistance caused by NHEJ ([@r47], [@r48], [@r70]); however, these hypotheses remain to be demonstrated. Notwithstanding, it will be interesting to determine if our *Ae. aegypti* Cas9 strains, each with varying expression in the germline, will be effective in a gene drive system designed for *Ae. aegypti*. This would be straightforward to test in a molecularly confined safe split-gene drive design where the Cas9 and the drive are positioned at different genomic loci. In this split-design, the Cas9 strains we developed can be directly tested without further modification by simply genetically crossing with a split gRNA-drive component and measuring rates of inheritance ([@r49], [@r71][@r72]--[@r73]).

While the CRISPR/Cas9 transgenic system developed here is quite effective, it would be useful to have the ability to supply the sgRNAs transgenically. In *D. melanogaster*, polymerase-3 promoters have been utilized to express sgRNAs, and through genetic crosses with Cas9 strains mutation efficiency could be increased up to 100% ([@r42], [@r43]).

Furthermore, it should be noted, that a slight disadvantage of these Cas9 strains for some groups may result from the fact that these strains were generated in the Liverpool genetic background, which restricts genome modifications to only this background. However, this can easily be overcome by simply using genetics to introgress these promoter-Cas9 transgenes into other genetic backgrounds, or by generating new transgenic strains in the desired background using the plasmids generated here.

Overall, our results demonstrate that our simplified transgenic Cas9 system has improved capacity to rapidly induce highly efficient and specific targeted genome modifications, including gene disruptions, deletions, and insertions. Given their high efficiencies, these Cas9 strains can be used to quickly generate genome modifications allowing for high-throughput gene targeting, thereby accelerating comprehensive functional annotation of the *Ae. aegypti* genome.

Materials and Methods {#s9}
=====================

Insect Rearing. {#s10}
---------------

Mosquitoes used in all experiments were derived from of the *Ae. aegypti* Liverpool strain, which was the source strain for the reference genome sequence ([@r58]).

Generation of *Ae. aegypti* Cas9 Transgenic Lines. {#s11}
--------------------------------------------------

Transgenic *Ae. aegypti* Cas9 mosquitoes were created by injecting 0- to 1-h-old preblastoderm-stage embryos with a mixture of *piggybac* vector containing the Cas9 expressing plasmid designed above (200 ng/μL) and a source of *piggyBac* transposase \[phsp-Pbac, (200 ng/μL)\] ([@r74][@r75]--[@r76]).

Characterization of AAEL010097-Cas9 Insertion Site. {#s12}
---------------------------------------------------

To characterize the Cas9 insertion site for AAEL010097-Cas9, we utilized a previously described inverse PCR protocol ([@r77]).

CRISPR Mediated Microinjections. {#s13}
--------------------------------

Embryonic collection and CRISPR microinjections were performed following previously established procedures ([@r30], [@r78]).
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